

Mayo to offer BioTheranostics' CancerType ID test, 12/13

[printfriendly]

December 2013—BioTheranostics announced that Mayo Clinic and Mayo Medical Laboratories will offer the company's CancerType ID molecular cancer classification test to aid in the management of patients with metastatic cancer.

As part of the agreement, the CancerType ID test will be available to Mayo Clinic physicians and patients as well as more than 5,000 hospitals around the world served by Mayo Medical Laboratories.

CancerType ID predicts tumor type in patients with metastatic cancers.

[**BioTheranostics**](#), 877-886-6739